These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24921213)

  • 1. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
    Wang W; Jiang CY; Wang HW
    J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
    [No Abstract]   [Full Text] [Related]  

  • 2. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
    Miki M; Kawabe K; Igarashi H; Abe T; Ohishi Y; Hashimoto R; Karashima T; Yamasaki I; Inoue K; Ito T; Ogawa Y
    Intern Med; 2018 Jul; 57(14):2007-2011. PubMed ID: 29491307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pancreatic neuroendocrine tumors and von Hippel-Lindau disease].
    Musso C; Paraf F; Petit B; Archambeaud-Mouveroux F; Valleix D; Labrousse F
    Ann Pathol; 2000 Mar; 20(2):130-3. PubMed ID: 10740008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
    Williams C; Walther M
    ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA; Valle JW
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
    Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
    Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
    Spiegel AM; Libutti SK
    Nat Rev Clin Oncol; 2011 May; 8(5):258-9. PubMed ID: 21448150
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Somatostatin Analog Therapy in a Patient With von Hippel-Lindau Disease and Multiple Pancreatic Neuroendocrine Tumors.
    OʼToole SM; Drake WM
    Pancreas; 2017 Aug; 46(7):e57. PubMed ID: 28697140
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in pancreatic neuroendocrine tumor treatment.
    Castellano D; Grande E; Barriuso J
    N Engl J Med; 2011 May; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late recurrence after surgical resection of a pancreatic tumor in von Hippel-Lindau disease.
    Corleto VD; Cotesta D; Petramala L; Panzuto F; Pagnini C; Masoni L; Verrienti A; Delle Fave G; Filetti S; Letizia C
    JOP; 2009 Sep; 10(5):562-5. PubMed ID: 19734639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
    Huda MS; Amiel SA; Ross P; Aylwin SJ
    Diabetes Care; 2014; 37(5):e87-8. PubMed ID: 24757248
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
    Zugazagoitia J; Sastre J; Barrera J; García B; Díaz-Rubio E
    J Cancer Res Ther; 2012; 8(2):303-5. PubMed ID: 22842382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in pancreatic neuroendocrine tumor treatment.
    van der Veldt AA; Kleijn SA
    N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
    [No Abstract]   [Full Text] [Related]  

  • 16. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
    [No Abstract]   [Full Text] [Related]  

  • 17. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

  • 18. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
    Raymond E; Ruszniewski P
    Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
    [No Abstract]   [Full Text] [Related]  

  • 19. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in pancreatic neuroendocrine tumor treatment.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 May; 364(19):1871-2; author reply 1873-4. PubMed ID: 21561357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.